VIDA
1.1K posts
@vida_intel_ai
VIDA is a clinical imaging intelligence company, accelerating the approval and adoption of life-saving therapies to patients through its AI-powered biomarkers.
Polarean Expands Xenon MRI Into Cardiopulmonary Drug Development Polarean has reached an important milestone by expanding the #XenonMRI platform into pharma-sponsored cardiopulmonary drug development through a multi-center U.S. study in pulmonary hypertension associated with interstitial lung disease (PH-ILD). In collaboration with a leading cardiopulmonary pharmaceutical company and @vidalung, this work leverages quantitative Xenon MRI biomarkers to directly measure treatment effects at the pulmonary capillary level, an area of lung physiology that has historically been difficult to assess with conventional tools. 🔬 Xenon MRI has the potential to support: ❇️ Early pharmacodynamic readouts in clinical studies ❇️ Differentiation between inhaled and systemic therapies based on mechanism of action ❇️ Improved patient characterization as predominantly left-heart disease (post-capillary) or right-heart disease (pre-capillary) ❇️ Greater endpoint sensitivity in cardiopulmonary clinical trials By pairing an inhaled therapy with an inhaled imaging signal, Xenon MRI delivers a noninvasive, radiation-free approach to quantify regional functional changes in lung ventilation, gas diffusion across the interstitial membrane, pulmonary capillary blood volume, and microvascular hemodynamics, all within a short breath hold. This expansion highlights Xenon MRI’s growing role as a powerful imaging biomarker platform for cardiopulmonary drug development, supporting precise evaluation of therapies in diseases with high unmet need. Read the full announcement: polarean.com/wp-content/upl… Arun Jose, MD, MS, @uofcincy, Sudar Rajagopal, MD, PhD, @DukeU, Leslie Spikes, @KUMedCenter #DrugDevelopment #ClinicalTrials #ImagingBiomarkers #PrecisionMedicine #Cardiopulmonary #PulmonaryHypertension #PH #ILD #PulmonaryImaging
